← Eichor
Condition: Locally Advanced Gastric Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Gastric Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi
Phase 2/Phase 3 · 10 location(s) · Beijing Biostar Pharmaceuticals Co., Ltd. · NCT06841679Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
Phase 2/Phase 3 · 10 location(s) · Leiden University Medical Center · NCT07018661A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemothera
Phase 2 · 1 location(s) · Shandong Provincial Hospital · NCT06829797Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06510010First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT06985602DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast
Phase 2 · 70 location(s) · AstraZeneca · NCT07069712A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastr
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06423885Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
Phase N/A · 1 location(s) · The First Hospital of Jilin University · NCT06881043A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Phase 3 · 1 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07103668Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · 106 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Phase 2/Phase 3 · 2 location(s) · Ukrainian Society of Clinical Oncology · NCT06028737QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Phase 3 · 1 location(s) · Chinese University of Hong Kong · NCT05264896Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Meta
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07152405Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2 · 3 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05687357A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.